Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer

Small cell lung cancer (SCLC) has a 5-year survival rate of <7%. Rapid emergence of acquired resistance to standard platinum-etoposide chemotherapy is common and improved therapies are required for this recalcitrant tumour. We exploit six paired pre-treatment and post-chemotherapy circulating tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenk, Maximilian W., Humphrey, Sam, Hossain, A. S. Md Mukarram, Revill, Mitchell, Pearsall, Sarah, Lallo, Alice, Brown, Stewart, Bratt, Samuel, Galvin, Melanie, Descamps, Tine, Zhou, Cong, Pearce, Simon P., Priest, Lynsey, Greenhalgh, Michelle, Chaturvedi, Anshuman, Kerr, Alastair, Blackhall, Fiona, Dive, Caroline, Frese, Kristopher K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599617/
https://www.ncbi.nlm.nih.gov/pubmed/34789728
http://dx.doi.org/10.1038/s41467-021-26823-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599617/
https://www.ncbi.nlm.nih.gov/pubmed/34789728
http://dx.doi.org/10.1038/s41467-021-26823-6

Ejemplares similares